Hormonal Disorders

Healthcare providers are increasingly looking for signs of opioid-induced adrenal insufficiency (OIAI) in their patients, according to a presentation made at the AACE annual meeting held in Los Angeles last week.

Primary care providers, endocrinologists and obstetricians have been challenged with the question of whether to screen all pregnant women for thyroid disease. The debate springs primarily from unknown clinical implications of subclinical thyroid disease during pregnancy. This issue was addressed at ENDO 2019.

The American Thyroid Association guidelines recommend repeat fine-needle aspiration, molecular testing or diagnostic surgical resection if thyroid nodule size increases significantly, but a new study shows there is little evidence that significant tumor growth is a predictor of malignancy, especially in architectural atypia of undetermined significance (AUS-A) cases.

Despite conflicting guidelines on how to treat hypothyroidism, U.S. physicians prescribe combination therapy more often than physicians around the world.

Our May list includes a new treatment for osteoporosis, predictors of thyroid cancer recurrence, and fast-acting vs conventional insulin for T1DM.

Our November list includes an injectable male contraceptive, resveratrol treatment for PCOS, and novel gene associated with Addison disease.

Is thyroid cancer the exception to the rule that alcohol consumption is linked to an increased risk of developing cancer?

Recent findings in thyroid cancer treatment, including laser ablation therapy, lenvatinib, and guidelines for treating pediatric patients, are shown in the following slides.